Telix Pharmaceuticals Limited American Depositary Receipt (TLX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XFRA Summary
Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 86.2% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents Transcript
Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents Transcript
Telix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving Up
Telix Pharmaceuticals Limited offers a potent mix of derisking, downside cushion, and accelerating clinical/commercial momentum in the radiopharmaceutical and diagnostic space. TLX reported Q1 revenue of $230M (up 11% QoQ), reaffirmed FY26 guidance of $950M–$970M, and expects further upside from new diagnostic approvals. Strategic collaborations (notably with Regeneron) and high-profile board appointments reinforce TLX's growth trajectory and potential acquisition appeal.
Telix Pharmaceuticals Limited American Depositary Receipt Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| YA Yinka Akinsola Blue Trust Inc. | 742 | $5,557.58 | $7,798.42 | $2,240.84 | 40.32% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 150,138 | $1.43M | $1.58M | $145,633.86 | 10.17% |
 Brian Baylis Bell Investment Advisors Inc. | 70 | $669.9 | $735.7 | $65.8 | 9.82% |
 Parth Karia Capricorn Fund Managers Ltd. | 36,100 | $344,394 | $368,942 | $24,548 | 7.13% |
 Michael Byun SageView Advisory Group LLC | 2 | $15 | $21.02 | $6.02 | 40.13% |
Telix Pharmaceuticals Limited American Depositary Receipt (TLX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Telix Pharmaceuticals Limited American Depositary Receipt ever had a stock split?
Telix Pharmaceuticals Limited American Depositary Receipt Profile
| Biotechnology Industry | Healthcare Sector | Christian Behrenbruch CEO | NASDAQ (NGS) Exchange | 87961M105 CUSIP |
| AU Country | 1,136 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Telix Pharmaceuticals Limited is a biopharmaceutical company that is in the commercial stage, with a primary focus on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. These products are designed for managing and treating cancer and rare diseases. The company operates across multiple regions, including Australia, Belgium, Japan, Switzerland, and the United States. Founded in 2015, Telix Pharmaceuticals has its headquarters located in North Melbourne, Australia. Through its innovative research and development activities, the company aims to bring new solutions to the medical field, particularly in oncology and radiopharmacy.
Products and Services
- Illuccix
This is a diagnostic and therapeutic product designed for the treatment of prostate cancer, showcasing Telix Pharmaceuticals’ contribution towards improving prostate cancer care.
- TLX66-CDx (for imaging osteomyelitis)
A diagnostic radiopharmaceutical specifically developed for imaging osteomyelitis, aiding in the diagnosis and management of this complex bone infection.
- TLX591
A radio antibody-drug conjugate aimed at treating prostate cancer, representing an innovative approach in targeting cancer cells directly with radiotherapy.
- TLX250-CDx
Designed for the treatment and diagnosis of renal (kidney) cancer, TLX250-CDx brings new hope for patients with this type of cancer through targeted therapy and diagnostics.
- TLX101-CDx
This product candidate is focused on brain (glioma) cancer, offering a potential new way to treat and diagnose one of the most challenging forms of cancer.
- TLX66-CDx (for bone marrow conditioning)
Developed for bone marrow conditioning, this radiopharmaceutical aims to prepare patients for hematopoietic cell transplantation, an important treatment for various blood disorders.
- TLX300-CDx
A product candidate for the treatment and diagnosis of soft tissue sarcoma, TLX300-CDx represents a targeted approach to managing this type of cancer.
- TLX250
For the treatment of clear cell renal cell carcinoma, TLX250 stands out as a therapeutic development, offering a new avenue for treating kidney cancer.
- TLX101
Specifically being developed for the treatment of glioblastoma (brain cancer), TLX101 is part of Telix Pharmaceuticals’ efforts to combat one of the most aggressive cancers.
- TLX66 (for bone marrow conditioning)
Another treatment avenue for bone marrow conditioning, highlighting Telix Pharmaceuticals’ commitment to supporting patients undergoing hematopoietic cell transplantation.
- TLX300
Aimed at treating soft tissue sarcoma, TLX300 focuses on delivering targeted therapy for this challenging cancer, potentially improving patient outcomes.
- TLX592
A prostate cancer therapy candidate designed for targeted alpha therapy, TLX592 is an example of the company’s innovative work in developing new cancer treatments.
